Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Investing

FDA Finally Allows OTC Access to One Brand of “Minipill”—A Mini‐​step in the Right Direction

by July 13, 2023
July 13, 2023

Jeffrey A. Singer

The Food and Drug Administration announced this morning that it has granted marketing approval for the over‐​the‐​counter sale of one type of birth control pill, a progestin‐​only pill (also called the “minipill”). As explained here, the minipill is not as easy to use as combination oral contraceptives. Dublin‐​based Perrigo, the maker of the pill that will have the brand name Opill, states it hopes to have the pill on the market by 2024.

As Josh Bloom and I wrote in May, enabling women to access this one brand of minipill is a ministep in the right direction. But the FDA should allow all women to access all forms of hormonal contraception over‐​the‐​counter.

Below are other articles I have written on the topic:

FDA Might Approve Over‐​the‐​Counter Sales of One Birth Control Pill. Now It’s Time To Approve All the Rest
Hey FDA, Free the Birth Control Pill!
OTC Birth Control Pills–Just What The Doctor Ordered
LA Times: Birth control should be available over the counter. How Congress can make that happen
NY Daily News: Over‐​the‐​counter birth control? Bring it on
Time: Women Should Not Have to Visit a Doctor for Birth Control

0
FacebookTwitterGoogle +Pinterest
previous post
5 Notable Reasons Why Your Business Should Invest in SEO
next post
American Compass Dystopia: “Rebuilding” American Capitalism

You may also like

What’s Driving the Drop in Overdose Deaths?

May 15, 2025

Does Section 3 of the Fourteenth Amendment Disqualify...

August 25, 2023

If the Office of Civil Rights Is Removed...

April 4, 2025

Four Reasons School Choice Is Good, but Federal...

May 13, 2025

CDC Survey Finds Record Low Number of Adult...

April 28, 2023

Leftist Victory in Mexico Puts Freedom at Risk

June 3, 2024

CBO Update: Medicare and Social Security Are Key...

June 25, 2024

The Best Way to Expand Naloxone Access? Clear...

May 22, 2025

Title 42 Failed. It Should Not Be Extended...

May 10, 2023

Did the Fentanyl Wave Hit Oregon Just as...

February 6, 2024

What’s Driving the Drop in Overdose Deaths?

May 15, 2025

Does Section 3 of the Fourteenth Amendment Disqualify...

August 25, 2023

If the Office of Civil Rights Is Removed...

April 4, 2025

Four Reasons School Choice Is Good, but Federal...

May 13, 2025

CDC Survey Finds Record Low Number of Adult...

April 28, 2023

Leftist Victory in Mexico Puts Freedom at Risk

June 3, 2024

CBO Update: Medicare and Social Security Are Key...

June 25, 2024

The Best Way to Expand Naloxone Access? Clear...

May 22, 2025

Title 42 Failed. It Should Not Be Extended...

May 10, 2023

Did the Fentanyl Wave Hit Oregon Just as...

February 6, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • One Big Bloated Blunder: What’s Wrong with the Senate’s Reconciliation Bill

      June 30, 2025
    • From Pain Points to Profit: Tour Operator Booking Software as a Key in Digital Transformation

      June 30, 2025
    • Bank Secrecy Act and Capital Gains Targeted for Reform at Bitcoin Policy Summit

      June 30, 2025
    • A Fresh Contender in Online Trading – But Does It Deliver?

      June 30, 2025
    • Supreme Court to hear Republican challenge that could shake up US elections

      June 30, 2025
    • Exiled Iranian prince tells Trump he can be ‘one of history’s great peacemakers’ amid talk of regime change

      June 30, 2025

    Categories

    • Business (8,345)
    • Investing (2,084)
    • Politics (15,875)
    • Stocks (3,178)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved